🚀 How we unlocked the first neuroscience target for the Recursion and Genentech collaboration.
The collaboration began with a mission to unlock new targets in one of medicine's most challenging therapeutic areas: neuroscience. Today, that work has reached an important
Decoding biology to radically improve lives. The industrial revolution of drug discovery is here.
- Join us on Wednesday, August 5 at 8am ET / 6am MT / 1pm BST for our Q2 2026 Earnings Call where we'll provide business updates and report our second quarter 2026 financial results. x.com/i/broadcasts/1… Questions may be submitted at: forms.gle/UGRGWTckLVJAq1…
- Today, Recursion reports its second quarter financial results and business updates, showing demonstrated progress across partnerships, clinical programs, and financial goals. 🚀 Highlights include: ▪️Genentech advanced the collaboration's first neuroscience target into a joint
- Recursion will host its second quarter financial results and business updates in an Earnings Call on August 5, 2026 at 8:00 am ET / 6:00 am MT / 1:00 pm BST. Join the call on: ▪️LinkedIn: linkedin.com/company/recurs… ▪️YouTube: youtube.com/@RecursionPhar… ▪️X: x.com/RecursionPharma
- We’re improving clinical trials with AI before the first patient enrolls. A new article from Brian Buntz in @RandDWorld highlights the current roadblocks in clinical trials and how Recursion is improving the process with a data- and AI-driven approach. Today, protocols are on

